Table 3

Clinical characteristics of DM patients with versus without anti-Mi-2

All DM

Number = 66

Mexico City DM

Number = 46

Guadalajara DM

Number = 20


Anti-Mi-2

(+)

Anti-Mi-2

(-)

Anti-Mi-2

(+)

Anti-Mi-2

(-)

Anti-Mi-2

(+)

Anti-Mi-2

(-)


Number

30

36

27

19

3

17

Age

41.3

44.1

42.0

50.3

34.7

37.2

(mean ± SD)

± 14.2

± 16.3

± 14.7a

± 15.1a, b

± 4.5

± 15.3b

% male

37%

22%

33%

26%

67%

18%

Shawl sign

86%c

61%c

85%

78%d

100%

40%d

Heliotrope

74%

79%

71%

89%

100%

69%

Gottrön

78%

74%

79%

78%

67%

69%

Malignancy

0%

6%

0%

11%

0%

0%

Fever

30%

25%

25%

28%

67%

21%

Calcinosis

7%

9%

4%

5%

33%

13%

ILD

7%

9%

4%

17%

50%

0%

Initial CPK IU/L

(mean ± SD)

5,369

± 4,124e

2,860

± 5,183e

4,800

± 3,111f

3,502

± 6,068f, g

NA

1,808

± 3,475g

Initial CPK

< 200 IU/L

0%h

34%h

0%i

22%i, j

NA

55%j

Initial CPK

> 1,000 IU/L

100%k

52%k

100%l

67%l, m

NA

27%m

Initial CPK

> 5,000 IU/L

54%n

14%n

52%o

17%o

NA

9%

Last CPK

> 500 IU/L

37%p

7%p

15%

0%

NA

18%

Last CPK

< 200 IU/L

45%

69%

45%

67%

NA

73%


aP < 0.05; bP < 0.005; cP < 0.05; dP < 0.05; eP < 0.0005; fP < 0.01; gnot significant; hP < 0.005; iP < 0.05; jP = 0.11; kP < 0.0001; lP < 0.005; mP = 0.06; nP < 0.005; 15, oP < 0.05; pP = 0.095. CPK, creatine phosphokinase; DM, dermatomyositis; ILD, interstitial lung disease; NA, not applicable (due to small numbers).

Petri et al. Arthritis Research & Therapy 2013 15:R48   doi:10.1186/ar4207

Open Data